{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-25-009076","form_type":"8-K","ticker":"NTHI","cik":"0001979414","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.205215+00:00","generated_at":"2026-05-16T21:45:37.590950+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"NEO100 yields 21% radiographic response & 44% 6mo PFS in recurrent IDH1-mutant gliomas","bullets":["Radiographic response rate of 21% (5/24) in recurrent Grade III/IV IDH1-mutant astrocytoma, exceeding <8% benchmark for salvage therapies.","Six-month progression-free survival (PFS-6) of 44% (8/18 evaluable) vs historical 21-31%.","33% of patients (8/24) alive ≥18 months post-NEO100 initiation; median overall survival 88 months.","No significant toxicity with chronic intranasal dosing; enrollment completed at 25 patients.","CEO calls data a potential paradigm shift; company advancing to Phase 2b/3 and global trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-25-009076","json":"https://secwatch.observer/filing/0001829126-25-009076.json","markdown":"https://secwatch.observer/filing/0001829126-25-009076.md","text":"https://secwatch.observer/filing/0001829126-25-009076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1979414/000182912625009076/0001829126-25-009076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1979414/000182912625009076/neonctechnologies_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:45:37.590950+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}